FDA Approves Edwards' PASCAL Precision System for Tricuspid Valve Repair
What happened
The U.S. Food and Drug Administration approved Edwards Lifesciences' PASCAL Precision system for tricuspid valve repair. The system is indicated for patients with symptomatic severe tricuspid regurgitation who are at intermediate or greater risk for surgery. With this approval, Edwards is now the only company providing a portfolio of repair and replacement transcatheter therapies for the mitral and tricuspid valves in the United States.
From dicardiology.com
Why it matters
The approval allows Edwards to support the treatment of a broader group of tricuspid patients. This establishes Edwards as the sole provider of these specific transcatheter therapies in the U.S.
Edwards Lifesciences develops products designed to treat advanced cardiovascular diseases.
From dicardiology.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- EdwardsSpeculative
Edwards could see increased sales and revenue due to its market dominance in this therapy.